Close Menu

NEW YORK – Proscia said on Tuesday that it will collaborate with Johns Hopkins School of Medicine on the development of computational applications that incorporate artificial intelligence to advance the practice of pathology for multiple diseases.

Terms of the agreement were not disclosed.

The collaboration adds to a number of academic and commercial institutions that Proscia is working with to bring disease-specific AI applications to market, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.